Cure8 research brief
Perianal fistulizing Crohn's disease is a frequent, hard-to-treat complication; molecular and multiomic advances could lead to biomarkers that help choose better-targeted therapies and improve surgical–medical decision making.
Patients with perianal Crohn's disease, gastroenterologists, colorectal surgeons, and researchers in IBD biology and biomarker development.
This is a review article (abstract-level content available) that synthesizes recent single-cell, spatial, and multiomic studies of fistula tissue and rectal mucosa.
The authors discuss how immune, stromal, epithelial, and microbial features identified by these methods expand understanding of PFCD biology and may enable biomarker development to stratify patients for different therapies.
The review also critically examines current and emerging pharmacological approaches and highlights the need to integrate molecular biomarkers with anatomical phenotype, surgical context, and standardized, multidimensional outcome measures for fistula healing.
Because the available content is an abstract, the brief summarizes the review's scope rather than detailed findings or specific biomarker candidates.
This entry is an abstract-level review on PubMed summarizing recent single-cell, spatial, and multiomic studies; it synthesizes existing research rather than reporting new trial results. Full-text review is needed for specific biomarker candidates or therapy recommendations.
Review the original publication for the complete reporting, methods, and context.
Conflict statement: Declaration of interests V.S. declares consulting fees from Janssen and Celltrion; speaker’s fees from Pfizer, Takeda, Giuliani, and Tillotts; travel grant from Eli Lilly and AbbVie. L.B. has received lecture fees, consultancy fees, or advisory board honoraria from AbbVie, Aliveda, Bromatech, Celltrion, Eli Lilly, Ferring, Johnson & Johnson, Giuliani, Italfarmaco, Lionhealth, Malesci, Noos, Novo Nordisk, PharmExtracta, PharmaNutra, Pfizer, Schwabe Pharma, and Takeda. L.A. has received lecture fees, consultancy fees, or advisory board honoraria from Alfasigma, Celltrion, Eli Lilly, Johnson & Johnson, and UCB. The other authors declare no competing interests.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
This review highlights shared biomarkers and mechanisms between early Crohn's disease and post-operative recurrence, which could improve prediction and lead to preventive strategies for recurrence after surgery.
Based on the title and source metadata, this appears to be a systematic review or meta analysis related to Crohn's disease, Inflammatory bowel disease, and Biomarkers. The original article is from Frontiers in medicine.
This analysis directly addresses treatments commonly used for perianal fistulizing Crohn’s disease and compares biologic anti-TNF drugs with emerging mesenchymal stem cell therapy, information that could affect treatment...
